The estimated Net Worth of Thomas Des Rosier is at least $1.11 Milion dollars as of 15 August 2024. Mr. Rosier owns over 2,656 units of Seres Therapeutics Inc stock worth over $131,298 and over the last 8 years he sold MCRB stock worth over $0. In addition, he makes $977,341 as Chief Legal Officer a Executive Vice President and Secretary at Seres Therapeutics Inc.
Sign up
Mr. DesRosier MCRB stock SEC Form 4 insiders trading
Thomas has made over 5 trades of the Seres Therapeutics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 2,656 units of MCRB stock worth $2,789 on 15 August 2024.
The largest trade he's ever made was exercising 25,000 units of Seres Therapeutics Inc stock on 26 January 2020 worth over $26,250. On average, Thomas trades about 3,888 units every 119 days since 2016. As of 15 August 2024 he still owns at least 125,046 units of Seres Therapeutics Inc stock.
You can see the complete history of Mr. Rosier stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Thomas DesRosier biography
Thomas J. DesRosier J.D. serves as Chief Legal Officer, Executive Vice President and Secretary of the Company. Previously, he served as Executive Vice President, Chief Legal and Administrative Officer and Secretary of ARIAD Pharmaceuticals, Inc., a biopharmaceutical company, from 2015 to 2016, Executive Vice President, Chief Legal and Administrative Officer and Secretary of Cubist Pharmaceuticals, Inc. (“Cubist”), a biopharmaceutical company, from 2014 to 2015 and Senior Vice President, Chief Legal Officer and Secretary of Cubist from 2013 to 2014. Before that, Mr. DesRosier served as Senior Vice President, General Counsel North America of Sanofi S.A., a global biopharmaceutical company, from 2011 to 2013. From 1999 to 2011, Mr. DesRosier held leadership roles of increasing seniority within the legal group of Genzyme Corporation, a biotechnology company, culminating in his role as Senior Vice President, Chief Legal Officer. Mr. DesRosier serves as a member of the board of directors of Avanir Pharmaceuticals, a wholly-owned subsidiary of Otsuka Pharmaceutical Company, Ltd. Mr. DesRosier earned a B.A. in Chemistry from the University of Vermont and a J.D. from Wake Forest University School of Law.
What is the salary of Thomas DesRosier?
As the Chief Legal Officer a Executive Vice President and Secretary of Seres Therapeutics Inc, the total compensation of Thomas DesRosier at Seres Therapeutics Inc is $977,341. There are 2 executives at Seres Therapeutics Inc getting paid more, with Eric Shaff having the highest compensation of $2,032,550.
How old is Thomas DesRosier?
Thomas DesRosier is 65, he's been the Chief Legal Officer a Executive Vice President and Secretary of Seres Therapeutics Inc since 2016. There are 3 older and 17 younger executives at Seres Therapeutics Inc. The oldest executive at Seres Therapeutics Inc is Dennis Ausiello, 74, who is the Independent Director.
What's Thomas DesRosier's mailing address?
Thomas's mailing address filed with the SEC is C/O SERES THERAPEUTICS, INC., 101 CAMBRIDGE PARK DRIVE, CAMBRIDGE, MA, 02140.
Insiders trading at Seres Therapeutics Inc
Over the last 9 years, insiders at Seres Therapeutics Inc have traded over $37,132,594 worth of Seres Therapeutics Inc stock and bought 17,627,131 units worth $47,525,463 . The most active insiders traders include Noubar Afeyan, Health Ltp Fund General Par... a Health Science Us Holdings,.... On average, Seres Therapeutics Inc executives and independent directors trade stock every 35 days with the average trade being worth of $251,393. The most recent stock trade was executed by Thomas Des Rosier on 15 August 2024, trading 2,656 units of MCRB stock currently worth $2,789.
What does Seres Therapeutics Inc do?
seres therapeutics is a clinical stage biotherapeutic company focused on discovering and developing ecobiotic™ therapeutic products, novel drugs to treat important diseases by targeting the underlying biology of the human microbiome. founded by flagship venturelabs, seres is pioneering the first therapeutics that catalyze a shift to health by augmenting the biology of the microbiome. current candidates span infectious, metabolic, and inflammatory diseases. for more information, please visit http://serestherapeutics.com/.
What does Seres Therapeutics Inc's logo look like?
Complete history of Mr. Rosier stock trades at Seres Therapeutics Inc
Seres Therapeutics Inc executives and stock owners
Seres Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Eric Shaff,
President, Chief Executive Officer, Director -
Eric D. Shaff M.B.A.,
Pres, CEO & Director -
Thomas DesRosier,
Chief Legal Officer, Executive Vice President and Secretary -
Matthew Henn,
Executive Vice President, Chief Scientific Officer -
Thomas J. DesRosier,
Chief Legal Officer, Exec. VP & Sec. -
Dr. David S. Ege Ph.D.,
Exec. VP & Chief Technology Officer -
Richard Kender,
Independent Director -
Kurt Graves,
Independent Director -
Meryl Zausner,
Independent Director -
Willard Dere,
Independent Director -
Gregory Behar,
Independent Director -
Dennis Ausiello,
Independent Director -
Stephen Berenson,
Independent Chairman of the Board -
David Ege,
Executive Vice President, Chief Technology Officer -
Jayne Gansler,
Chief People Officer, Executive Vice President -
Terri Young,
Executive Vice President, Chief Commercial and Strategy Officer -
Lisa von Moltke,
Executive Vice President, Chief Medical Officer -
Paul Biondi,
Independent Director -
Carlo Tanzi,
Head of Investor Relations and Corporate Communications -
John Aunins,
Executive Vice President of Bioprocess & Manufacturing and Chief Technology Officer -
Marcus Chapman,
Senior Vice President - Finance and Principal Financial and Accounting Officer -
Dr. John G. Aunins Ph.D.,
Sr. Advisor -
Dr. Matthew R. Henn Ph.D.,
Exec. VP & Chief Scientific Officer -
David A. Arkowitz M.B.A.,
Exec. VP, CFO & Head of Bus. Devel. -
James R. Weston,
Sr. VP of Regulatory Affairs -
Jayne M. Gansler,
Exec. VP & Chief People Officer -
Jeff York,
VP of HR -
Noubar Flagship Ventures Fu...,
-
Peter Barton Hutt,
Director -
Michele Trucksis,
See Remarks -
David N Cook,
See Remarks -
Noubar Afeyan,
Director -
Health Science Us Holdings,...,
-
Lorence H. Kim,
Director -
Wael Hashad,
EVP & Chief Commercial Officer -
Teresa L. Young,
See Remarks -
Paula Cloghessy,
See Remarks -
Marella Thorell,
See Remarks -
Roger Pomerantz,
President and CEO -
Kevin Horgan,
Chief Medical Officer and EVP -
Werner Cautreels,
Director -
Noubar Flagship Ventures Fu...,
-
Ventures Fund Iv General Pa...,
-
Health Ltp Fund General Par...,
-
David Arkowitz,
Chief Financial Officer -
Health Ltp Fund General Par...,
-
Claire Fraser,